BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27821317)

  • 41. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
    Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
    Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
    Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
    JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.
    Rauch GM; Kuerer HM; Adrada B; Santiago L; Moseley T; Candelaria RP; Arribas E; Sun J; Leung JWT; Krishnamurthy S; Yang WT
    Ann Surg Oncol; 2018 Jul; 25(7):1953-1960. PubMed ID: 29667115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
    Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
    Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
    Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
    Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.
    Frati A; Chereau E; Coutant C; Bezu C; Antoine M; Chopier J; Daraï E; Uzan S; Gligorov J; Rouzier R
    Breast Cancer Res Treat; 2012 Apr; 132(2):601-7. PubMed ID: 22160638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
    Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
    van Loevezijn AA; van der Noordaa MEM; van Werkhoven ED; Loo CE; Winter-Warnars GAO; Wiersma T; van de Vijver KK; Groen EJ; Blanken-Peeters CFJM; Zonneveld BJGL; Sonke GS; van Duijnhoven FH; Vrancken Peeters MTFD
    Ann Surg Oncol; 2021 Jun; 28(6):3243-3253. PubMed ID: 33263830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
    Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
    Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast lesions with imaging-histologic discordance during 16-gauge core needle biopsy system: would vacuum-assisted removal get significantly more definitive histologic diagnosis than vacuum-assisted biopsy?
    Wang ZL; Liu G; Li JL; Su L; Liu XJ; Wang W; Tang J
    Breast J; 2011; 17(5):456-61. PubMed ID: 21762244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of recurrence rates on change in hormone receptor and human epidermal growth factor receptor 2 status after neo-adjuvant chemotherapy in breast cancer patients].
    Tokunaga S; Ikeda K; Ogawa Y; Fukushima H; Inoue T; Shibata Y; Kimbara S; Katsushima U; Okada H; Tsuya A; Taira K; Daga H; Takeda K
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):313-6. PubMed ID: 24743275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):552-62. PubMed ID: 18398094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Digital breast tomosynthesis-guided vacuum-assisted breast biopsy: initial experiences and comparison with prone stereotactic vacuum-assisted biopsy.
    Schrading S; Distelmaier M; Dirrichs T; Detering S; Brolund L; Strobel K; Kuhl CK
    Radiology; 2015 Mar; 274(3):654-62. PubMed ID: 25386875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients.
    Koelbel V; Pfob A; Schaefgen B; Sinn P; Feisst M; Golatta M; Gomez C; Stieber A; Bach P; Rauch G; Heil J
    Ann Surg Oncol; 2022 Feb; 29(2):1076-1084. PubMed ID: 34581923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer.
    Bhattacharyya M; Ryan D; Carpenter R; Vinnicombe S; Gallagher CJ
    Br J Cancer; 2008 Jan; 98(2):289-93. PubMed ID: 18219287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Factors related with pathological complete response of neoadjuvant chemotherapy in primary breast cancer].
    Cheng YJ; Ye JM; Xu L; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Apr; 51(4):339-43. PubMed ID: 23895756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.